EWA
ESPR

EverSource Wealth Advisors’s Esperion Therapeutics ESPR Stock Holding History

EverSource Wealth Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65K Sell
521
-426
-45% -$1.19K ﹤0.01% 3796
2026
Q1 		$2.6K Buy
947
+33
+4% +$104 ﹤0.01% 3548
2025
Q4 		$3.38K Hold
914
– – ﹤0.01% 3289
2025
Q3 		$2.42K Buy
914
+37
+4% +$72 ﹤0.01% 3458
2025
Q2 		$863 Buy
877
+568
+184% +$569 ﹤0.01% 3767
2025
Q1 		$445 Buy
309
+152
+97% +$280 ﹤0.01% 3494
2024
Q4 		$345 Buy
+157
New +$366 ﹤0.01% 3306

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

EverSource Wealth Advisors's ESPR Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Esperion Therapeutics (ESPR) stake by 45% in Q2 2026, selling an estimated $1.19K and leaving 521 shares worth $1.65K. The position accounts for ﹤0.01% of the portfolio, ranked #3796.

EverSource Wealth Advisors first reported a position in ESPR in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.38K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • EverSource Wealth Advisors held 521 shares of Esperion Therapeutics worth $1.65K as of Q2 2026.
  • EverSource Wealth Advisors sold 426 Esperion Therapeutics shares in Q2 2026, an estimated $1.19K.
  • Esperion Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3796 holding.
  • EverSource Wealth Advisors first reported a position in Esperion Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • EverSource Wealth Advisors's Esperion Therapeutics position peaked at $3.38K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.